5 Exacerbation-prone Phenotypes Were Discovered Among Asthma and COPD Patients
April 14th 2022Five phenotype clusters were discovered to be associated with the exacerbation, or worsening, of chronic inflammatory airway diseases of asthma and chronic obstructive pulmonary disease (COPD), according to a recent study published in PLOS ONE.
Read More
More Evidence of Mental Health Services Shifting to Telehealth: Health Affairs Study
April 13th 2022Findings published in the April issue of Health Affairs show a huge jump in telehealth visits, but the researchers also detected that a pattern that suggests that people with conditions such as schizophrenia did not make the switch to telehealth as readily as people with anxiety and some other disorders.
Read More
Finding a Way Forward for Public Health - Greater Investment, Greater Distrust
April 13th 2022“The most remarkable change in patterns of health during the (past) century has been the largely successful conquest of infectious diseases,” wrote Allan Brandt, Harvard medical historian, in “No Magic Bullet: A Social History of Venereal Disease in the United States Since 1880."
Read More
FDA Updates for Week of April 4, 2022
April 9th 2022The FDA approves novel therapy for schizophrenia and bipolar and grants accelerated approval to treat rare disorder. The agency also accepted the sBLA and has granted priority review for Actemra or the treatment of COVID-19 and has extended the PDUFA date for vutrisiran.
Read More
Humira Biosimilars Are Hitting the Market in 2023. Finally. But Will Prescriptions Follow?
April 7th 2022Marcus Snow, MD, , chair of the American College of Rheumatology’s Committee on Rheumatologic Care, discusses how additional clinical data and interchangeability designations could help build momentum for use of Humira (adalimumab) biosimilars when they start to arrive in 2023.
Read More
Briana Contreras, editor of Managed Healthcare Executive spoke with Emad Rizk, M.D., chairman, president, and CEO of Cotiviti in this week's episode of Tuning In to the C-Suite. In the discussion, they talked about the issues of risk in healthcare and how they have led to inequalities in care. They also addressed how adopting risk assessment tools that expand access to data around social determinants of health can help reduce bias and improve care.
Listen
Biosimilars Are Supposed to Save Money. Providence St. Joseph Health Has Made That Happen.
April 6th 2022Using an aggressive utilization management approach, Providence St. Joseph Health directed physicians toward the use of biosimilars immediately after they came to market, saving nearly $27 million over two years in the process, according to Sophia Z. Humphreys, Pharm.D., M.H.A., the healthcare system’s director of system pharmacy clinical Services.
Read More